Insider Trading March 16, 2026 08:07 PM

OraSure CFO Adds $66,029 to Personal Stake as Company Prepares 2026 Product Rollout

Kenneth McGrath executed a Rule 10b5-1 purchase of 22,021 OSUR shares; recent results show revenue miss and ongoing margin and funding pressures

By Jordan Park OSUR

OraSure Technologies Chief Financial Officer Kenneth J. McGrath purchased 22,021 shares on March 13, 2026, under a pre-set trading plan, spending $66,029 at an average price of $2.9985 per share. The company reported Q4 2025 revenue of $26.8 million, below analyst expectations, while warning of continued funding and operational losses even as it works to improve gross margins and plans new product introductions in 2026. The stock trades at $3.13, up 29% year-to-date but below InvestingPro's Fair Value estimate.

OraSure CFO Adds $66,029 to Personal Stake as Company Prepares 2026 Product Rollout
OSUR

Key Points

  • OraSure CFO Kenneth J. McGrath bought 22,021 shares on March 13, 2026, at a weighted average price of $2.9985, totaling $66,029.
  • The purchase was made under a Rule 10b5-1 trading plan adopted November 28, 2025; after the transaction McGrath directly owns 557,262 shares.
  • OraSure reported Q4 2025 revenue of $26.8 million, a roughly 4.6% miss versus the $28.08 million expectation; company is working on gross margin improvements and plans new product launches in 2026.

OraSure Technologies (NASDAQ:OSUR) disclosed a personal purchase by its chief financial officer, Kenneth J. McGrath, who acquired 22,021 shares of the companys common stock on March 13, 2026. According to the Form 4 filed with the Securities and Exchange Commission, the buy was executed at a weighted average price of $2.9985 per share, with individual trade prices ranging from $2.93 to $3.12. The total value of the transaction was $66,029.

The transaction was carried out under a prearranged Rule 10b5-1 trading plan that McGrath adopted on November 28, 2025. After completing this purchase, McGraths direct holdings in OraSure amount to 557,262 shares.

Market action has lifted the stock 29% year-to-date, with the share price at $3.13 at the time of the filing. That price remains below InvestingPros Fair Value estimate, a circumstance the firm indicates suggests the shares may still be undervalued.


Separately, OraSure reported fourth-quarter 2025 results that showed revenue of $26.8 million, missing the anticipated $28.08 million forecast by roughly 4.6%. The company said it is working to improve gross margins but continues to contend with funding constraints and operational losses. Management has indicated plans to bring new products to market in 2026, which the company views as potential drivers of future growth.

The combination of a recent insider purchase, a year-to-date rally, and results that fell short of expectations paints a mixed picture for investors. The insider purchase was modest in value relative to typical institutional flows, while the earnings miss and the ongoing need for funding underline continued execution and financing risks.

InvestingPro subscribers are noted to have access to 10 additional tips specifically about OSUR, as well as access to Pro Research Reports that cover more than 1,400 U.S. stocks. These services are described as sources of further analysis and information for those monitoring the ticker.

Given the companys stated plans for product launches in 2026 and the disclosed operational headwinds, market participants will likely watch upcoming execution milestones and financing developments closely to gauge whether the shares can re-rate toward the stated fair value benchmark.

Risks

  • Revenue shortfall in Q4 2025 and ongoing operational losses indicate execution risk for OraSure - impacts healthcare and medtech market participants.
  • Funding constraints identified by the company signal potential financing risk that could affect product development and commercialization timelines - relevant to biotech and medical device investors.
  • Current share price being below InvestingPros Fair Value estimate suggests valuation uncertainty for equity investors pending proof of operational improvement and successful product launches.

More from Insider Trading

Ultragenyx Executive Executes Stock Sale Amidst Financial Headwinds May 6, 2026 Kaltura Executive Executes Scheduled Stock Sale Amidst Platform Expansion May 6, 2026 Kaltura Executive Natan Israeli Executes Planned Stock Sale Amid Strategic AI Expansion May 6, 2026 Andersons Director Executes $1.33 Million Stock Sale Amid Mixed Quarterly Results May 6, 2026 Halliburton Executive Maxwell Casey Executes Rule 10b5-1 Stock Sale Valued at Over $850,000 May 6, 2026